Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junrong Yan

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Journal of Medical Virology|October 27, 2017
Performance evaluation of Cepheid Xpert Norovirus kit with a user-modified protocolRachel Shi-Lei Wong, Fion Yeo, Wai Theng Chia, et al.
Clinical and Translational Medicine|September 8, 2020
Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of responseJingjing Li, Qing Wei, Xiaoying Wu, et al.
Science Advances|January 9, 2026
Impaired nitrogenous waste clearance promotes hepatocellular carcinomaXinlu Han, Jianliang Shen, Junrong Yan, et al.
Cellular and Molecular Gastroenterology and Hepatology|January 22, 2021
The Ubiquitin E3 Ligase TRIM21 Promotes Hepatocarcinogenesis by Suppressing the p62-Keap1-Nrf2 Antioxidant PathwayFang Wang, Ye Zhang, Jianliang Shen, et al.
BMC Medicine|July 22, 2025
Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancersJiaojiao Ni, Chaoqun Li, Xiaoqing Xu, et al.
Biorxiv : the Preprint Server for Biology|February 9, 2026
OSTM1 is a ubiquitin E3 ligase that suppresses B-cell malignancy by activating the cAMP/PKA/CREB pathwayMuhammad Usama Tariq, Namratha Sheshadri, Jianliang Shen, et al.
Oncogene|December 14, 2019
Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutationYing Jin, Hua Bao, Xiuning Le, et al.
Oncogene|November 23, 2019
Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutationYing Jin, Hua Bao, Xiuning Le, et al.
Nature Communications|March 28, 2020
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinomaLi Ren Kong, Nur Afiqah Binte Mohamed Salleh, Richard Weijie Ong, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Journal of Medical Virology|October 27, 2017
Performance evaluation of Cepheid Xpert Norovirus kit with a user-modified protocolRachel Shi-Lei Wong, Fion Yeo, Wai Theng Chia, et al.
Clinical and Translational Medicine|September 8, 2020
Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of responseJingjing Li, Qing Wei, Xiaoying Wu, et al.
Science Advances|January 9, 2026
Impaired nitrogenous waste clearance promotes hepatocellular carcinomaXinlu Han, Jianliang Shen, Junrong Yan, et al.
Cellular and Molecular Gastroenterology and Hepatology|January 22, 2021
The Ubiquitin E3 Ligase TRIM21 Promotes Hepatocarcinogenesis by Suppressing the p62-Keap1-Nrf2 Antioxidant PathwayFang Wang, Ye Zhang, Jianliang Shen, et al.
BMC Medicine|July 22, 2025
Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancersJiaojiao Ni, Chaoqun Li, Xiaoqing Xu, et al.
Biorxiv : the Preprint Server for Biology|February 9, 2026
OSTM1 is a ubiquitin E3 ligase that suppresses B-cell malignancy by activating the cAMP/PKA/CREB pathwayMuhammad Usama Tariq, Namratha Sheshadri, Jianliang Shen, et al.
Oncogene|December 14, 2019
Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutationYing Jin, Hua Bao, Xiuning Le, et al.
Oncogene|November 23, 2019
Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutationYing Jin, Hua Bao, Xiuning Le, et al.
Nature Communications|March 28, 2020
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinomaLi Ren Kong, Nur Afiqah Binte Mohamed Salleh, Richard Weijie Ong, et al.
Pageof 7